UC Davis Health is scheduling COVID-19 vaccines

Get the latest on how to schedule your COVID-19 vaccine, boosters and third doses, and more.

Scientific knowledge of COVID-19 treatments continues to grow, but there is still more to learn. UC Davis has played an important role in the global effort to find effective science-based care for COVID-19 patients and will continue to adapt treatments as research advances.

Remdesivir (brand name Veklury) and monoclonal antibody therapy are being used to control viral infection (or replication), and dexamethasone is used to control the immune response to infection. These treatments assist with recovery for those diagnosed with COVID-19. These drugs have often proven more successful than using a ventilator, which sometimes has made lung inflammation worse.

Monoclonal antibodies are like the antibodies naturally made by the human body to fight viruses. They are designed to target the coronavirus spike protein. When the antibodies bind to the spike protein, they block the virus from entering the body’s cells. This keeps the virus from making copies of itself and continuing to spread in the body.

Monoclonal antibodies protect against severe illness by overwhelming the coronavirus infection while it's still mostly in the nose and throat. However, the treatment remains limited because it needs to be given within a week after COVID-19 symptoms first appear. This can be an issue because people don't always know when they were exposed or how long they've been infected.

Patients diagnosed with COVID-19 have the option to receive a monoclonal antibody treatment, which has been shown to reduce COVID-19-related hospitalization or deaths in high-risk patients. Early treatment with this therapy can reduce the risks of COVID-19, but it will not protect you against catching the virus. It is also not a substitute for getting the COVID-19 vaccine.

Learn why monoclonal antibody treatment isn't a substitute for the COVID-19 vaccine

Remdesivir is an antiviral drug. It targets the replication and progression of viral infections such as the novel coronavirus. It is being tested as a treatment for COVID‑19 and has been authorized for emergency use for people with severe symptoms. However, it’s not yet known whether it is a safe and effective treatment. Experimental use at UC Davis Medical Center suggests the drug could have benefits for very ill patients. UC Davis Health is currently conducting two clinical trials with the drug to evaluate its efficacy.

Please talk to your physician about treatments and prevention for COVID-19 before taking anything. Learn more about the FDA’s warning of taking ivermectin for COVID-19

Researchers and health providers say there is evidence that an antibody treatment may help boost an individual’s protective immune response. They have identified the powerful antibodies that fight infections such as the one that causes COVID-19. This treatment, popularly known as an “antibody cocktail,” is being tested with sick patients and people who have been exposed to the virus. These types of treatments have shown promise against other viruses, such as Ebola.

UC Davis Health is conducting a clinical trial to test the effectiveness and safety of REGN-COV2, a monoclonal antibody cocktail used in preventing COVID-19 in adults living with infected patients. This is the same drug administered to President Trump as part of his treatment for COVID-19 infection. This trial, which is in Phase III, is sponsored by Regeneron Pharmaceuticals. The antibody approaches could serve as an important bridge until a vaccine is widely available, according to the company.

Learn more about this antibody cocktail clinical trial

An analysis of seven studies of severely ill COVID-19 patients treated with corticosteroids, including dexamethasone, found the drugs significantly helped reduced deaths from the disease. The World Health Organization now strongly recommends steroids for treatment of patients with severe or critical COVID-19 worldwide, but it recommended against steroid use when the disease is mild. The international clinical trials studied dexamethasone, hydrocortisone and methylprednisolone – inexpensive and widely available steroids commonly used to reduce inflammation and moderate the body’s immune system.

Yes, but perhaps not at the same levels as during the early stages of the pandemic. The National Institutes for Health (NIH) has developed guidelines for adults with COVID-19 who are receiving supplemental oxygen. The NIH recommends close monitoring for worsening respiratory status and the use of a mechanical ventilator, if it becomes necessary. However, experts also say that when COVID-19 patients require mechanical ventilation, there is risk of lung injury due to the ventilation itself. Physicians are being very thoughtful about the use of ventilators because of those concerns. We have changed our treatment methods as more research becomes available and are trying to avoid using ventilators when possible, due to the negative effects they can have on lung inflammation.

Hydroxychloroquine is an arthritis medicine and anti-malaria treatment that also has been tried as a COVID-19 treatment. The Infectious Diseases Society of America revised its COVID-19 treatment guidelines in September 2021, recommending against its use for hospitalized patients with COVID-19. Hydroxychloroquine may have significant side effects, including reports of serious heart rhythm problems and other safety issues, blood and lymph system disorders, kidney injuries, and liver problems and failure.

UC Davis Health is working on effective treatments to increase the survival rate of people with COVID-19. As noted above, we have changed our treatment methods as more research becomes available. We're trying to avoid using ventilators when possible, due to the negative effects they can have on lung inflammation.